Latest Intelligence on Heart Failure in North America

Select information type

Refine your search

search
Search tips

by geography

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

AstraZeneca: Toprol ruling worsens generic woes

AstraZeneca has been left facing a significant revenue loss after a US court ruled that two Toprol XL patents were invalid. In the face of this new generic threat, combined with existing challenges to the company's other blockbuster drugs and its weak pipeline, AstraZeneca can now only hope its strategy of in-licensing products can be relied upon to keep the money coming in.

Published By Datamonitor
20 Jan 2006
CommentWire
CommentWire

Cardiome: heart failure

Cardiome Pharma has revealed that its phase II study investigating the safety and efficacy of oxypurinol in heart failure patients failed to meet both the primary and secondary endpoints, sparking debate over oxypurinol's future. Indeed, it looks like Cardiome may now have to put all of its eggs into one basket, depending on its other pipeline drug, RSD1235.

Published By Datamonitor
17 Aug 2005
ResearchWire
ResearchWire

Heart failure: pipeline dominated by approved drugs

Published By Datamonitor
31 Aug 2007
CommentWire
CommentWire

Heart failure: quality of care is a gamble in US hospitals

A study funded by Scios has found that four standard treatment measures key to treating heart failure are unwittingly withheld in a number of US hospitals. In order to address this issue, hospitals should look to improve educational programs for physicians, as well as considering an increase in the use of certain key cardiovascular drugs.

Published By Datamonitor
15 Jul 2005
CommentWire
CommentWire

Pfizer: Inspra to be a cardio blockbuster

The approval of Pfizer's [PFE] Inspra (eplerenone) for post-MI heart failure patients, based on the EPHESUS trial results, should be sufficient for use of the drug to exceed that of its less well tolerated predecessor, spironolactone. With marketing support from Pfizer, Inspra is all set for blockbuster status.

Published By Datamonitor
13 Oct 2003
CommentWire
CommentWire

Protein Design Labs: hope in heart failure

Protein Design Labs has unveiled positive results from a phase II study assessing ularitide in acute decompensated congestive heart failure. These results will support further studies of ularitide, and hopefully progression to phase III trials. However, the company must be cautious regarding the drug candidate's progression, as a late-stage failure would come as a significant blow.

Published By Datamonitor
07 Sep 2005

« | 1 | » »|

No help is available.